Some infections can start inflammation that, while controlling the infection, can also attack the body tissues of genetically susceptible people. This inflammation can initiate long term problems including arthritis, diabetes and cancer. Our research program seeks to understand who is genetically at risk of this sort of problem and why, and thus to develop new means to prevent and treat the chronic diseases that are initiated in this way.
Risk Factors, Early Diagnosis, And Effective Interventions For Neurocognitive Disorders
Funder
National Health and Medical Research Council
Funding Amount
$7,013,299.00
Summary
This program will focus on early detection of dementia, identification of novel risk factors, and development of new treatments, to help the burden of dementia in our community. It will build on three longitudinal studies – Memory and Ageing Study, Older Australian Twins Study and Sydney Centenarian Study, and three international consortia – COSMIC, STROKOG and ICC-Dementia, that the investigators have developed to achieve these aims. A prevention trial for post-stroke dementia is planned
Development And Evaluation Of An Internet-based Clinic For Stuttering.
Funder
National Health and Medical Research Council
Funding Amount
$6,200,965.00
Summary
Stuttering is a prevalent disorder of speech production. The program of research will establish the world’s first Internet-based stuttering clinic to service all the clinical needs of child, adolescent and adult patients. The Internet-based clinic model will provide economical, scalable and translatable stuttering treatments that will, for the first time, provide a means to adequately manage the public health problem of stuttering.
Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
Molecular Determinants Of Susceptibility And Progression In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$6,006,551.00
Summary
Breast cancer is heterogeneous, making management a challenge. High-grade cancers including the ‘basal’ type are aggressive, often found in young women and have a propensity for distant spread. They are also associated with a BRCA1 gene mutation. We will study mechanisms that predispose some women to develop breast cancer, the process that allows cancers to grow at distant sites such as the brain and lungs, and how DNA repair proteins are implicated. This will allow development of new diagnostic ....Breast cancer is heterogeneous, making management a challenge. High-grade cancers including the ‘basal’ type are aggressive, often found in young women and have a propensity for distant spread. They are also associated with a BRCA1 gene mutation. We will study mechanisms that predispose some women to develop breast cancer, the process that allows cancers to grow at distant sites such as the brain and lungs, and how DNA repair proteins are implicated. This will allow development of new diagnostic tools and treatments.Read moreRead less
The Elimination Of Hepatitis C As A Global Public Health Threat
Funder
National Health and Medical Research Council
Funding Amount
$7,001,475.00
Summary
In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2 ....In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2030.Read moreRead less
Mental Health Of Young People With Developmental Disabilities
Funder
National Health and Medical Research Council
Funding Amount
$5,622,916.00
Summary
Mental health problems of people with developmental disabilities are a substantial public health problem. A large Australian study shows that the problem begins early and persists without intervention. We will evaluate the Stepping Stones Triple P model of parenting early intervention after adding newly developed modules for specific causes of ID. The effectiveness of the program across three states will be evaluated.
Frontotemporal Dementia And Motor Neurodegenerative Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$17,069,580.00
Summary
Frontotemporal degeneration of the brain is a leading cause of morbidity due to a pathologically heterogeneous, rapidly-progressive group of disorders with behavioural, language and motor deficits. Our internationally recognized team will continue to develop the necessary tools and therapies to effectively diagnose, manage and treat these disorders. Our focus in this program is to understand the unusual genetics underpinning these disorders, and to fast track any potential treatments.
We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells. We wish to learn how cancer can sometimes evade the immune system. Our work will also find out how some common treatments for cancer, like chemotherapy, can be used to boost the immune system and eliminate tumours. Through knowledge gained from these studies, we aim to develop new therapies that can help patients with devastating diseases like cancer.